Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
US FDA Performance Tracker Approvals Regulation

Keeping Track: Merck & Co. In Spotlight With Welireg, Keytruda Approvals; FibroGen/AZ Roxadustat CRL Is No Surprise

  • Analysis

Executive Summary

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

You may also be interested in...



Medicare Dialysis Bundle And New Drugs: Will Transitional Payments Work For Korsuva, Vadadustat?

Quick provider uptake will be key for upcoming new drugs covered by the Medicare end stage renal disease prospective payment system.

Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip
Scrip
Scrip
Pink Sheet
Scrip

Topics

Related Companies

Tags:
US FDA Performance Tracker Approvals Regulation
Latest Headlines

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS

Moderna And The All-American Drug Pricing Hearing

US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval

See All
UsernamePublicRestriction

Register

PS144803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By